Manganello Francesca, Mungo Giuseppe, Rettore Donatella, Otaño Ruiz Esther, Frungillo Antonio
Polimedica s.r.l. - Trebaseleghe (PD), Mirano (Venice), Italy.
MAR-FARMA Srl, Milan, Italy.
J Med Food. 2025 Mar;28(3):304-307. doi: 10.1089/jmf.2024.0214. Epub 2024 Nov 29.
Homocysteine (HCys) is a sulfur-containing amino acid involved in the conversion of methionine to cysteine. Elevated levels of HCys, known as hyperhomocysteinemia, have been associated with health risks, including cardiovascular and neurological disorders. This study examined the incidence of hyperhomocysteinemia in an unselected female population and evaluated the effectiveness of a Food for Special Medical Purposes (FSMPs), EUCIS PLUS, in reducing HCys levels.The study was divided into two phases: The first phase of the study, conducted at the Poliambulatorio Polimedica in Trebaseleghe (PD), evaluated the incidence of hyperhomocysteinemia in 181 women with an average age of 47.8 years; the second phase tested the effectiveness of EUCIS PLUS, a FSMPs, in reducing HCys levels in women with values above 10 µmol/L. During Phase 1, an incidence of hyperhomocysteinemia was observed in 81.2% of 181 women, with mean HCys levels of 15.4 µmol/L. Phase 2 involved treating 44 women with HCys >10 µmol/L using EUCIS PLUS, resulting in an average reduction of HCys levels by 36%, reaching 10.7 µmol/L after two months of treatment. Hyperomocysteinemia is an underdiagnosed risk condition. The results of this study highlight the importance of diagnosing and managing hyperhomocysteinemia and suggest that the FSMPs EUCIS PLUS can be an effective and well-tolerated therapeutic option.
同型半胱氨酸(HCys)是一种含硫氨基酸,参与蛋氨酸向半胱氨酸的转化。HCys水平升高,即高同型半胱氨酸血症,与包括心血管和神经疾病在内的健康风险相关。本研究调查了未经过筛选的女性人群中高同型半胱氨酸血症的发病率,并评估了一种特殊医学用途食品(FSMPs)EUCIS PLUS降低HCys水平的有效性。该研究分为两个阶段:研究的第一阶段在特雷巴塞莱盖(PD)的波利安布勒托里奥波利梅迪卡进行,评估了181名平均年龄为47.8岁的女性中高同型半胱氨酸血症的发病率;第二阶段测试了FSMPs EUCIS PLUS降低HCys水平高于10µmol/L的女性体内HCys水平的有效性。在第一阶段,181名女性中有81.2%观察到高同型半胱氨酸血症的发病率,平均HCys水平为15.4µmol/L。第二阶段使用EUCIS PLUS治疗44名HCys>10µmol/L的女性,结果HCys水平平均降低了36%,治疗两个月后降至10.7µmol/L。高同型半胱氨酸血症是一种诊断不足的风险状况。本研究结果突出了诊断和管理高同型半胱氨酸血症的重要性,并表明FSMPs EUCIS PLUS可以是一种有效且耐受性良好的治疗选择。